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Self-assembling heparin nanoparticles have attracted much attention as promising drug 
carriers for various drugs, genes and imaging agents. In the present investigation, we found 
that heparin nanoparticles are selective Toll-like receptor 4 (TLR-4) antagonists and have a 
much greater anti-inflammatory effect than native heparin. More specifically, we developed 
self-assembling nanoparticles composed of glycol-split heparin/D-erythro-sphingosine 
conjugates (NAHNP), characterized their physicochemical properties and anti-inflammatory 
effect in vitro. Unlike native heparin, NAHNP significantly inhibited lipopolysaccharide-
induced activation of MyD88 - dependent NF-κB signaling pathway and production of pro-
inflammatory cytokines such as TNF-alpha from mouse macrophages with IC50= 0.019 
mg/mL. Furthermore, we investigated the structure–activity relationship of the conjugates and 
identified the length of attached alkyl chains of D-erythro-sphingosine to be critical for anti-
inflammatory effect. Decrease in alkyl chain length of NAHNP resulted in loss of inhibitory 
activity. In line with these findings, 6-O-sulfate groups of D-glucosamine residue were 
essential for effective inhibition, while removal of 2-O-sulfo and 3-O-sulfo groups as well as 
replacement of N-sulfo groups with N-acetyl did not alter anti-inflammatory activity. 
Therefore, NAHNP would be a promising candidate in acute and chronic inflammatory 
























Polymeric or macromolecular micelles have extensively been studied as vehicles for targeted 
delivery of various drugs, genes and imaging agents. The micelles are self-assembled 
colloidal particles comprising amphiphilic molecules such as two-block copolymers and lipid-
grafted macromolecules. Among many carrier systems that have been developed, heparin-
based nanoparticles are one of the attractive ones [1]. As in the case of other materials, 
coating of nanoparticles with heparin can suppress complement- mediated opsonization [2, 3], 
and prolong retention in blood circulation [4]. Heparin-based nanoparticles have been applied 
as carriers for anti-cancer drugs [5], oxygen [6, 7] and anti-inflammatory metallic particles 
such as gold and silver [8]. Combination of heparin with pH-sensitive [9, 10] or temperature 
sensitive [11] polymers or with magnetically operatable nanoparticles [12] has also been 
investigated for targeted drug delivery. In addition to low toxicity and high biocompatibility, 
heparin has a variety of biological activities beyond anti-coagulation [13–15]. The intrinsic 
properties of heparin can provide additional functionality towards particulate carrier systems. 
One typical example is anti-angiogenic therapy to suppress tumor growth [16, 17]. Lipid-
conjugated heparin derivatives retain an ability to bind to angiogenic factors such as fibroblast 
growth factors and vascular endothelial growth factors, so that they can significantly decrease 
endothelial cell proliferation [18, 19]. Another interesting property of heparin is its anti-
inflammatory activity [13], although there is a lack of related reports dealing with heparin-
based nanoparticles [8]. Heparin can bind and inhibit proteins critically involved in 
inflammation, such as cytokines, growth factors, cytotoxic peptides, and tissue-destructive 
enzymes, thereby limiting the activation of inflammatory cells [13, 14]. It has been reported 
to be useful in inflammatory conditions such as arthritis [20], inflammatory bowel disease 
[21] and allergic rhinitis [22]. However, the clinical application of heparin for these 
conditions is limited by its anticoagulant effect or non-specificity of action [15]. Underlying 
mechanisms responsible for the anti-inflammatory effect of heparin are yet to be clarified [23], 
but notably heparin inhibits recruitment of leukocytes to inflammatory sites via blockade of 
P- and L-selectins which critically requires 6-O sulfation of glucosamine residues [24]. 
Furthermore, heparin inhibits adhesion and migration of leukocytes in the endothelium by 
binding to cell surface proteins such as β2-integrin adhesion molecule CD11b/CD18 and 
platelet/endothelial cell-adhesion molecule 1 [15]. In this study, we demonstrate that self-
assembling nanoparticles composed of glycol-split non-anticoagulant heparin–D-erythro-
sphingosine conjugates (NAHNP) are selective Toll-like receptor 4 (TLR4) antagonists and 
have a much greater anti-inflammatory activity than native heparin. This means that the 
heparin nanoparticles can block an initial step of pro-inflammatory reactions in primitive 
immune cells which is a different target from that of the above-mentioned action. TLR family 
members are critical for the development of innate and adaptive immunity in response to 
pathogens and endogenous ligands generated in damaged tissues [25]. TLRs, particularly 
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signaling through TLR4 have also been implicated in both the establishment of diseases such 
as arthritis [26], Alzheimer's disease [27], chronic myositis [28], and systemic lupus 
erythematosus [29] and their maintenance. Under circumstances when the immune system is 
disbalanced, inhibition of TLR4 signaling appears to be important in limiting the redundant 
response during the inflammation. Here we found that NAHNP blocks the production of 
tumor necrosis factor (TNF-α) from Escherichia coli lipopolysaccharide (LPS)-mediated 
stimulation of macrophages in vitro. Macrophages as essential cells of the innate immune 
system are a major source of pro-inflammatory cytokines after stimulation with LPS, a 
selective TLR4 agonist [30, 31]. In vitro experiments of the underlying mechanism using 
mouse macrophages suggested that the inhibitory effect of nanoparticles was due to the 
downregulation of MyD88-dependent nuclear factor-κB (NF-κB) signaling via TLR4 but not 
other TLRs. In addition, we investigated the structure–activity relationship for the anti-
inflammatory effects and elucidated functional groups in NAHNP needed for the activity. 
These results shed light on synergistic effects of anti-inflammatory drugs with the heparin-
based nanoparticulated carriers. 
 
2. Materials and methods 
2.1. Synthesis of glycol-split non-anticoagulant heparin D-erythro-sphingosine nanoparticles 
(NAHNP) 
Glycol-split non-anticoagulant heparin (NAH) was obtained by periodate-oxidation and 
borohydride-reduction of heparin (Nacalai Tesque, Inc., Kyoto, Japan) as described in the 
well-established method of Conrad et al. [32]. NAH then was dissolved in formamide with 
different amounts of 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide followed by the 
addition of different molarities of D-erythro-sphingosine (LKT Laboratories, Inc., St. Paul, 
MN) dissolved in dimethylformamide. 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide was 
maintained at a ratio of 5:1 with D-erythro-sphingosine. The reaction mixture was stirred at 
room temperature for 24 h under a nitrogen atmosphere. Afterwards, the reaction mixture was 
precipitated in pure ethanol, centrifuged 14,000 ×g for 10 min followed by decantation. This 
was repeated 3 times to remove any remaining unreacted D-erythro-sphingosine and reaction 
solutions. Precipitates were then dried in a vacuum and lyophilized as NAHNP. Self-
assembled nanoparticles of NAHNP were prepared by ultrasonication using a probe sonicator 
(UD-201, Tomy Seiko Co. Ltd., Japan) for 1 min in distilled water. Unfractionated heparin 
was used instead of NAH to synthesize native heparin nanoparticles (HPNP). 1H-NMR 
spectra were obtained with JEOL 400 spectrometers at 400 MHz (D2O : ethanol-D6 = 2.5:1 v/ 
v). In NAH, the C2-C3 bond of glucuronic acid is cleaved resulting in a shift in the H-2 and 
H-3 peaks (s, δ=3.38 ppm) of glucuronic acid causing them to shift under the peak of 6-O-
sulfoglucosamine H-2 (s, δ = 3.27 ppm). Chemical shifts for attached D-erythro-sphingosine 
were assigned: δ = 1.09 (t, H18, -CH3), 1.13 (m, H-7-H-17, -CH2 −), 2.90 (s, H-2), 3.61 (s, 
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H-1), 5.53 (s, H-4), 5.78 (s, H-5), 8.04 (s, CO-NH). Degree of substitution with D-erythro-
sphingosine was estimated using a direct titration method as described elsewhere [33].  
 
2.2. Synthesis of heparin derivatives 
2-O-desulfated and 6-O-desulfated heparins were prepared as reported previously [34, 35]. N-
desulfated re-N-acetylated heparin was prepared by the method of Nagasawa et al. [36]. 
Totally desulfated heparin was prepared by the method of Sudo et al. [37]. Resulting heparin 
derivatives then were periodate-oxidized and borohydride-reduced as described for native 
heparin [32]. D-erythro-sphingosine was then attached to carboxylic groups of each product 
using the method described above to synthesize 2-ODSNP, 6-ODSNP, NDSNP, TDSNP 
respectively. In 2-ODSNP, 2-O-sulfoiduronic acid is converted to iduronic acid. This was 
observed by an upfield shift of H-1 signal from5.13 ppm to 4.90 and H-2 signal from 4.30 
ppm to 4.17 ppm. In N-desulfonated samples the glucosamine H-2 signal of NAH assigned at 
3.27 ppm completely disappeared, whereas a downfield shifted signal at 3.31 ppm appeared, 
which was the signal for H-2 bearing an -NH2 substituent. A chemical shift of 6-O-
sulfoglucosamine H-1 (5.36 ppm) was observed upfield in 6-ODSNP compared to NAHNP 
(5.25 ppm). In totally desulfonated and re-N-acetylated nanoparticles (TDSNP), all the signals 
affected by N and O-sulfo groups on C-2 and C-3, C-6 of glucosamine and/or C-2 position of 
iduronic acid residues were found upfield compared to NAHNP.  
 
2.3. Synthesis of NAH-Octadecanamine (NAHOCT), NAH-Decanamine (NAHDEC) and 
NAH-Pentanamine (NAHPEN) conjugates 
NAH was first converted to chloroform soluble tetrabutylammonium salt. NAH (40 mg) was 
dissolved in water (80 mL) and passed through a Dowex 50WX8 (H + form, 200–400 mesh) 
column (0.8 × 10 cm) (Sigma-Aldrich) to exchange sodium ions to hydrogen ions. The acidic 
fraction was neutralized to pH 4.5with tetra-n-butylammonium hydroxide (40% in water) 
(Nacalai Tesque Inc., Kyoto, Japan) and lyophilized. NAH-tetrabutylammonium salt (20 mg) 
was then dissolved in chloroform (4 mL) following the addition of 5-fold molar excess of 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide and 1-octadecanamine (Sigma-Aldrich), 1-
decanamine (Sigma-Aldrich) or 1-pentanamine (Sigma-Aldrich). The reaction mixture was 
stirred at room temperature for 24 h. Then, chloroform was evaporated in rotary evaporator 
followed by addition of 10% sodium hydrogen carbonate and the solution was kept at room 
temperature for 2 h. Then, the mixture was dialyzed against water and lyophilized as 
NAHOCT, NAHDEC or NAHPEN. Chemical shifts for attached 1-octadecanaminewere 
assigned at δ=0.87 (t, H18,-CH3), 1.20 (m, H-2-H-17, -CH2−), 2.90 (m, H-1, -CH2−), 8.04 (s, 
CO-NH). Chemical shifts for attached 1-decanamine were assigned at δ = 0.86 (t, H10, -CH3), 
1.13 (t, H-3–H-9, -CH2−), 1.28 (m, H-2, -CH2−), 2.80 (t, H-1, -CH2−), 8.04 (s, CO-NH). 
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Chemical shifts for attached 1-pentanamine were assigned at δ=0.89 (t, H5, -CH3), 1.27 (m, 
H-2-H-4, -CH2−), 2.80 (m, H-1), 8.04 (s, CO-NH). 
 
2.4. Particle size and zeta potential measurements 
Size distribution and zeta potential values of nanoparticles were measured by Zetasizer Nano 
(Malvern Instruments, Worcestershire, UK).  
 
2.5. Electron microscopy studies 
Transmission electron microscopy (TEM) analysis was carried out using a HitachiH-
7650microscope (Hitachi Co., Tokyo, Japan) operating at 80 kV accelerating voltage. 
Samples were prepared by placing a drop of nanoparticle solution (0.1 mg/mL) on a 400 mesh 
copper grid (Nisshin EM Co., Tokyo, Japan). Excess liquid was allowed to air-dry. 
Nanoparticles were then negatively stained with 2% w/v uranyl acetate solution. Images were 
captured using an AMT camera system. 
 
2.6. Fluorescent probe studies  
Critical micelle concentration (CMC) values of NAHNPs with different degrees of 
substitution by D-erythro-sphingosine were determined by fluorescence spectroscopy using 
pyrene as a probe, as described by Kabanov et al. [38]. Fluorescence spectra were recorded 
using a Fluoromax-4 spectrofluorometer (Horiba Ltd, Kyoto, Japan) at 25 °C. A solution of 
pyrene in acetone was added to vials and acetone was evaporated, depositing a thin film of 
pyrene to the vial wall. Conjugate solutions (3 mL) varying in concentration between 0.005 
μg/mL and 1 mg/mL were then added to the flasks. The final pyrene concentration was 6.5 × 
10−7 M. The solutions were equilibrated overnight at 35 °C. The excitation and emission 
wavelengths were 339 and 390nm, respectively. Spectra were accumulated with an 
integration time of 1 s/nm. Pyrene fluorescence intensity was plotted versus log 
concentrations of conjugates at 25 °C. The CMC values were taken from the intersection of 
the tangent to the curve at the inflection with the horizontal tangent through the points at low 
concentrations. The aggregation number of associating polymeric assemblies in nanoparticles 
was determined using a fluorescence quenching technique as reported previously [39]. 
Cetylpyridinium chloride (CPC) was used as a quencher for pyrene and prepared just before 
the experiments were performed. We also investigated hydrophobicity of the core of 
nanoparticles by measuring the partitioning coefficient of pyrene between the aqueous and 
micellar phases as described previously [38]. 
 
2.7. Cell isolation and in vitro assay for cytokines 
Mouse peritoneal macrophages were isolated as described previously [40]. Briefly, cells were 
harvested from 5-week-old female ICR or C3H/HeJ mice 4 days after intraperitoneal injection 
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of 1 mL 2.9% thioglycollate medium (Nissui Pharmaceutical, Tokyo, Japan). Washed cells 
were suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) 
(Flow Laboratories, Irvine, UK), penicillin G (100 U/mL), and streptomycin (100 μg/mL), 
and then plated on 24-well plates (Falcon, Becton Dickinson, Lincoln Park, NJ, USA) at a 
density of 1.5 × 105 cells per well. After incubation for 2 h at 37 °C in a humidified 
atmosphere of 5% CO2 in air, non-adherent cells were washed off. The remaining cells were 
cultured for 24, 48, 72, or 96 h. After replacing the media with Opti-MEM® I Reduced Serum 
Medium (Gibco®, Life Technologies) containing nanoparticles (0.5 mg/mL final 
concentration) plus 20 ng/mL LPS (Sigma-Aldrich), cells were incubated for 24 h and the 
supernatant was assayed for cytokines using mouse TNF alpha ELISA kit (eBioscience, Inc.). 
Cells were also stimulated (where indicated) with 20 ng/mL PAM3CSK4 (InvivoGen), 20 
ng/mL flagellin (InvivoGen) and 10 μg/mL poly(I:C) (InvivoGen) in the presence or absence 
of nanoparticles. IC50 value was calculated from the curve fitted to the dose–response 
inhibitory profile.  
 
2.8. Western blotting 
Peritoneal macrophages were cultured in a 100 mm culture dish in 10% FBS/RPMI 1640, and 
then medium was changed to Opti-MEM I. Next, cells were stimulated with LPS (20 ng/mL) 
in the presence or absence of NAHNP (0.5 mg/mL) for the indicated times. Cytosol and 
nuclear extracts were prepared using The Nuclear Extract Kit (Active Motif) and subjected to 
SDS-PAGE, transferred onto PVDV membrane (GE Healthcare) and probed with rabbit IgG 
antibodies against phospho-IRAK-1 (pThr209, Sigma-Aldrich), IκB-α (Santa Cruz 
Biotechnology, Inc.), p50 (Abcam plc) and RelA (Abcamplc). Blots were visualized using 
ImageQuant LAS 4000 (GE Healthcare). 
 
2.9. Fluorescence-activated cell sorting (FACS) analysis 
To analyze the interaction of NAHNP with TLR4/MD2, we performed FACS analysis using 
FITC (Sigma-Aldrich) labeled NAHNP (NAHNPFITC). Nanoparticles were labeled with 
FITC following the manufacturer's instructions and purified using ethanol precipitation 
method. Thioglycollate-elicited mouse peritoneal macrophages were maintained in 12-well 
plate (Falcon, Becton Dickinson, Lincoln Park, NJ, USA) at a density of 5.0 × 106 cells per 
well in 10% FBS/RPMI 1640 at 37 °C, 5% CO2 in a humidified atmosphere. Cells were then 
washed with PBS and incubated with anti-mouse TLR4/MD2 monoclonal antibody (MTS510, 
eBioscience, Inc.) in blocking buffer (PBS + 5%FBS) for 1 h to neutralize the receptor. After 
three washes with PBS cells were treated with NAHNP-FITC (0.1 mg/mL) in Opti- MEM® I 
Reduced Serum Medium and incubated for additional 30 min. Next, cells were washed with 
PBS three times and harvested by scraping for FACS analysis using BD FACS Canto II (BD 
Bioscience, Franklin Lakes, NJ, USA). As a positive control, cells were incubated with 
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NAHNP-FITC (0.1 mg/mL) in Opti-MEM® I for 30 min at room temperature without 
receptor neutralization step. After the specified time the cells were washed with PBS three 
times and processed to FACS analysis. Unstimulated cells served as a negative control.  
 
2.10. Fluorescent microscopy 
To further confirm the specificity of nanoparticles binding to TLR4/MD2, an 
immunofluorescence imaging experiment was conducted using fluorescent microscopy, in 
which macrophages were first treated with the allophycocyanin (APC) conjugated 
monoclonal anti-mouse TLR4/MD2 (APC-anti-TLR4/MD2) antibody. Macrophages were 
incubated with APC-anti-TLR4/MD2 in blocking buffer in 35 mm glass bottom dishes (Iwaki, 
Asahi Glass Co., Ltd, Japan) at a density of 2.0 × 104 cells/cm2 for 1 h. After three washes 
with PBS cells were treated with NAHNP-FITC (0.1 mg/mL) in Opti-MEM® I and incubated 
for additional 30 min and mounted in the same dish for microscopic visualization. Nuclei 
were stained by incubating cells with Hoechst 33342 (1 μg/mL) for 5 min prior to observation 
at room temperature. Positive control cells were treated with NAHNP-FITC (0.1 mg/mL) in 
Opti-MEM® I without TLR4/MD2 neutralization step and were incubated for 30 min before 
monitoring. We used Nikon Eclipse Ti inverted microscope equipped with A1R MP 
multiphoton confocal system (Nikon Instruments Inc., Tokyo, Japan) with hybrid scanning 
head which incorporates both a galvano scanner and an ultrahigh-speed resonant scanner. 
Images were processed with NIS Elements AR acquisition and analysis software (Nikon 
Instruments Inc., Tokyo, Japan). 
 
2.11. In vitro cytotoxicity assay 
Cell viability after nanoparticle treatment was determined using 2-(4-Iodophenyl)-3-(4-
nitrophenyl)-5-(2,4-disulfophenyl)-2Htetrazolium salt (WST-1) based colorimetric assay 
according to the manufacturer's instructions (Roche Applied Biosystems). 
 
2.12. Statistics 
We used GraphPad Prism 5.0 (GraphPad Software, Inc.) to perform statistical tests. Data are 
presented as means ± SEM for each group. Experiments involving two groups were analyzed 
by two-tailed, unpaired t test. P < 0.05 was considered statistically significant. 
 
3. Results 
3.1. Synthesis and characterization of nanoparticles 
NAH derivative was produced by glycol-splitting of C2\C3 bonds of nonsulfated D-
glucuronic acid residues of native heparin [32, 41]. This also led to enhanced chain flexibility 
of the glycosaminoglycan (GAG) backbone. D-erythro-sphingosine was covalently attached 
to carboxylic groups of NAH (Fig. 1A). These conjugates self-assemble to form core-shell 
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nanoparticles above the CMC. TEM analysis demonstrated nanoparticles were uniformly 
spherical (Fig. 1B). Physicochemical characteristics of the nanoparticles are summarized in 
Table 1. Increasing the degree of substitution with D-erythro-sphingosine affected the 
physicochemical parameters of the nanoparticles by decreasing size and CMC (see Fig. 1C 
and Supplementary Fig. S1). Partitioning coefficient (Kp) of pyrene between the micellar and 
aqueous phases, an indicator of hydrophobicity, increased with increasing the degree of 
substitution (Supplementary Fig. S2). The aggregation number (nagg) from fluorescent 
quenching measurements increased upon increasing the degree of substitution 
(Supplementary Fig. S3) whereas concurrently particles tended to decrease in size. Thus, lipid 
substitution strengthened hydrophobic interactions within the core. Zeta potential was highly 
negative indicating heparin chains covered the particles (Fig. 1D).  
 
3.2. Effect of NAHNP on TLR4-mediated NF-κB signaling and production of TNF-α 
The nanoparticles significantly inhibited in vitro production of TNF-α from E. coli 
lipopolysaccharide (LPS)-activated mouse peritoneal macrophages (Fig. 2A). Native heparin 
or NAH had no significant effect (Fig. 2B). Analysis of dose–response curves for NAHNP 
yielded the 50% inhibitory concentration (IC50) value of 0.019 mg/mL for inhibition of 
macrophage derived TNF-α production (Fig. 3). IC50 values were expressed as a percentage 
of the positive control and calculated as described above for the ELISA inhibition 
experiments. Inhibitory potency of nanoparticles with different degrees of substitution was 
not significantly different. To determine whether inhibition occurred by suppressing TLR4- 
mediated NF-κB signaling, the ability of NAHNP to inhibit cytokine release induced by 
specific extracellular TLR ligands was assessed. TNF-α production in response to TLR1/2 
(Pam3CSK4), TLR3 (poly (I:C)) and TLR5 (flagellin) ligands was unaltered by NAHNP (Fig. 
4A). NAHNP did not inhibit cytokine synthesis in macrophages with TLR4 mutations 
(TLR4Lps-d) isolated fromC3H/HeJ mice (Fig. 4B). TLR4Lps-d cells were unresponsive to 
LPS but did respond to Pam3CSK4, poly (I:C) or flagellin (Fig. 4B). The effect of NAHNP 
on activation of intracellular signaling molecules in the TLR4-mediated MyD88-dependent 
NF-κB pathway was examined. NAHNP prevented phosphorylation of interleukin-1 receptor-
associated kinase-1 (IRAK-1), a signaling molecule downstream of MyD88 (Fig. 5). LPS-
induced cytoplasmic degradation of inhibitor of NF-κB (IκBα) was blocked by NAHNP 
treatment. Nuclear extracts from LPS-treated cells revealed markedly suppressed nuclear 
localization of NF-κB p50/RelA subunits in the presence of NAHNP compared to controls 
(Fig. 5). 
 
3.3. In vitro cytotoxicity of heparin nanoparticles 
Nanoparticles were tested for cytotoxicity using primary cultured mouse peritoneal 
macrophages. Following 24 h of continuous exposure to the nanoparticles, cell viability was 
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determined usingWST-1 assay. Nanoparticles did not appear to be toxic (cell viability of 
greater than 80%) at concentrations up to 5mg/mL under tested conditions (Fig. 6).  
 
3.4. Interaction of nanoparticles with TLR4/MD2 
In order to confirm the interaction of NAHNP with the cell surface and to evaluate its 
TLR4/MD2 targeting specificity, the ligand–receptor binding of the nanoparticles was 
investigated using FACS and fluorescent microscopy. Binding of NAHNP-FITC to the cells 
was monitored with higher fluorescence signal; on the other hand, it was inhibited when 
TLR4/MD2 receptor complex was neutralized with anti-TLR4/MD2monoclonal antibody. 
The histograms of both conditions are compared in Fig. 7A. Interaction of the nanoparticles 
with TLR4/MD2 was further observed using fluorescent microscopy. As shown in Fig. 7B 
fluorescent signal of NAHNP-FITC was distributed over the cell surface (green in b, c) which 
was completely blocked by preincubation with APC-anti- TLR4/MD2 antibody (red in e, f). 
These results were consistent with the results of FACS analysis. We also evaluated the 
inhibitory effect of nanoparticles after 30min LPS-exposure and observed that nanoparticles 
inhibited TNF-α production from the macrophages at this time point (Fig. 7C). These results 
demonstrate that macrophages do not take up nanoparticles within 30 min, with the majority 
of nanoparticles being distributed over the surface of the cells and possessing the biological 
activity through TLR4/MD2 interaction.  
 
3.5. Structure–activity relationship (SAR) 
HPNP had a smaller anti-inflammatory effect than NAHNP in vitro (Fig. 8A) indicating the 
critical role of glycol-splitting. Glycol-splitting resulted in loss of anti-coagulant properties 
(data not shown) and significantly increased anti-inflammatory activity of nanoparticles. To 
explore the detailed SAR of nanoparticles, we examined the involvement of sulfo groups and 
the effect of alkyl chain length in the anti-inflammatory effect. A series of nanoparticles with 
regioselectively modified NAH were prepared. NAH was selectively 2-O-desulfated (2- 
ODSNP), 6-O-desulfated (6-ODSNP), N-desulfated re-N-acetylated (NDSNP) and totally 
desulfated (TDSNP) prior to D-erythro-sphingosine attachment to carboxylic groups of each 
derivative (Supplementary Fig. S4). In addition, conjugates where D-erythro-sphingosine of 
NAHNP was replaced with 1-octadecanamine (NAHOCT), 1- decanamine (NAHDEC) or 1-
pentanamine (NAHPEN) was synthesized (Supplementary Fig. S5). To compare activities, 
TNF-α produced by mouse peritoneal macrophages treated with LPS in the presence or 
absence of test compounds was measured. Selective desulfation of N-sulfo (at C-2 of the D-
glucosamine residues) and 2-O-sulfo (at C-2 of L-iduronic or D-glucuronic acid residues) 
groups did not affect the anti-inflammatory properties of NAHNP (Fig. 8B). In contrast, 
removal of 6- O-sulfate groups (at C-6 of D-glucosamine residues) reduced the anti-
inflammatory potency. Thus, 6-O-sulfo groups contributed to the anti-inflammatory effect 
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(Fig. 8B). Totally desulfated nanoparticles retained an anti-inflammatory effect but were less 
effective than those with sulfo groups at C-6 position (Fig. 8B). Changes in the length of acyl 
chains altered the activity of NAHNP. Thus, NAHDEC and NAHPEN conjugates showed no 
inhibitory effect (Fig. 8C). All samples were pyrogen-free to avoid endotoxin contamination 
in vitro. Nanoparticles retained an inhibitory effect when D-erythro-sphingosine was replaced 
with lipids containing the same length of alkyl chain, such as 1- octadecanamine (Fig. 8C). 
 
4. Discussion 
We synthesized nanoparticles self-assembled from the amphiphilic conjugates of glycol-split 
heparin/D-erythro-sphingosine, which exhibit anti-inflammatory properties. Glycol-splitting 
of native heparin prior to conjugation with lipid strongly enhanced its anti-inflammatory 
properties. Nanoparticles possess high stability in aqueous solutions aggregating at low CMC 
of conjugates and have high hydrophobicity of inner core. However, their physicochemical 
characteristics are affected by the degree of substitution with D-erythro-sphingosine. 
Nanoparticles comprising a higher substituted conjugate (NAHNP10) could form more stable 
self-assemblies, thus might be more promising candidates for in vivo drug delivery and 
therapeutics. Anti-inflammatory effects of heparin were mediated through the ability of 
heparin to bind and inactivate proteins such as complement components, chemokines, growth 
factors, tissue destructive enzymes and adhesion molecules such as L- and P-selectins 
involved in recruitment of inflammatory cells [13, 14, 24]. In vitro studies showed that 
glycol-split heparin nanoparticles suppressed the production of TNF-α from LPS-stimulated 
macrophages by inhibiting TLR4-mediated NF-κB signaling with IC50 = 0.019 mg/mL. It is 
well known that interaction of LPS with TLR4–MD-2 receptor complexes results in activation 
of the MyD88-dependent downstream signaling pathway. This pathway induces the 
phosphorylation and degradation of IκBα, which in turn allows active NF-κB to translocate to 
the nucleus and induce proinflammatory cytokine gene expression. The recruitment and 
phosphorylation of IRAK1 is specific to the MyD88-dependent signaling pathway [42]. Early 
prevention of IRAK-1 phosphorylation by LPS treatment in the presence of NAHNP 
suggested the MyD88 signaling pathway was not activated. Interaction of NAHNP with 
TLR4/MD2 receptor complex was further confirmed by FACS analysis and visualized by 
fluorescent microscopy. We showed that inhibitory activity of nanoparticles was specific to 
cell surface TLR4/MD2, since no binding was detected after neutralization of the receptor. 
Furthermore, nanoparticles were effective against LPS stimulation of macrophages from the 
early minutes of exposure, when particles were observed to be accumulated over the cell 
surface. This is, to our knowledge, the first demonstration that lipid-modified heparin 
derivatives exhibit elevated anti-inflammatory properties by functioning as TLR4 antagonists 
through the TLR4–MyD88 pathway. Since the particles are covered with heparin chains, their 
surface charge is provided by sulfo and D-erythro-sphingosine unsubstituted carboxyl groups 
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and consequently, the most common type of interaction between surface heparins and their 
targets would be ionic. However, chain flexibility [43], non-electrostatic interactions such as 
hydrogen bonding and hydrophobic interactions also contribute to GAG–protein complex 
stability [44, 45]. Structure activity relationship studies were conducted to assess which 
chemical group in the nanoparticle heparin backbone might contribute to its anti-
inflammatory activity. Blockade of L- and P-selectins require D-glucosamine 6-O-sulfation of 
the GAG chain in native heparin [24]. Our results showed that selective removal of 6-O-sulfo 
groups at C-6 of D-glucosamine decreased its activity. The TLR4–MD-2 receptor complex 
has affinity with amphiphilic lipid A and its analogs, and is sensitive to the nature and length 
of acyl chains and the interaction with charged groups on the hydrophilic portion of ligands 
[46–48]. Crystal structures of antagonistic (lipid IVa, Eritoran) binding to TLR4–MD-2 show 
that di-glucosamine residues do not interact directly with MD-2 whereas lipid chains interact 
with MD-2 through hydrophobic contacts. D-erythro-sphingosine chains of NAHNP could 
interact in a similar manner to those of acyl chains in TLR4 synthetic antagonists whereas 
decreased chain lengths of NAHNP may affect these interactions, resulting in loss of 
inhibitory activity. However, detailed structural analysis is required to reveal the role of ionic 
interactions of 6-O-sulfo groups and evaluate receptor ligand interactions at the molecular 
level.  
 
5. Conclusion  
We show that glycol-split heparin conjugated with alkyl amines forms stable self-assembling 
nanoparticles in aqueous solutions. These nanoparticles exhibit anti-inflammatory effect and 
effectively suppress TNF-α from LPS-stimulated macrophages. This effect is mediated 
through the inhibition of the TLR4–NF-κB pathway. This is to our knowledge, the first report 
showing that lipid-modified heparin derivatives possess elevated anti-inflammatory properties 
by functioning as TLR4 antagonists. SAR analysis of these non-anticoagulant heparin 
nanoparticles revealed the importance of 6-O-sulfo group and the length of alkyl chain of 
attached hydrophobic moiety in anti-inflammatory activity. However, additional 
pharmacological and toxicological studies are required to evaluate whether the nanoparticles 
can be used in clinical settings. 
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NAHNP1 1:1 160±2.6 –55.6±2.1 0.29±0.03 3.57 30.5±2.8 0.47 8.1·104 0.68 
NAHNP10 1:10 110±3.4 –30.1±1.7 0.32±0.02 8.20 77.4±4.9 0.013 1.0·105 0.70 
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Partitioning coefficient of pyrene in distilled water in presence of NAHNP 
conjugates. 
g
Partial specific volume in water at 25 C determined using a pycnometer. Results 



























Fig. 1. Structure and formation of non-anticoagulant heparin nanoparticles. (A) Chemical 
structure of NAHNP. (B) Nanoparticles were stained with uranyl acetate and visualized using 
transmission electron microscopy. Scale bar: 100 nm.  (C) Particle size distribution of 
NAHNP1 (top) and NAHNP10 (bottom) in water after 1 min ultrasonication. (D) Zeta 
potential distribution of NAHNP1 (top) and NAHNP10 (bottom). 
Fig. 2. Inhibitory effect of NAHNP on in vitro production of TNF- via TLR4. Quantification 
of TNF- from peritoneal macrophages isolated from wild-type mice. Cells (1.5×105 cells per 
well) were seeded to 24-well-plates and were not treated (NT) or stimulated with LPS (20 
ng/mL) for 24 hours in the presence or absence of 0.5 mg/mL NAHNP (A), native heparin or 
NAH (B). Data are shown as mean SEM (n=3). ** P  0.01. 
Fig. 3. Dose-dependent effect of NAHNP on TNF- production from LPS-stimulated 
macrophages after 24h. The results are given as mean SEM (n=3), by expressing the 
inhibition of cytokine-producing cells as a percentage of LPS-stimulated non-drug-exposed 
macrophages. Non-stimulated cells were used as negative controls. 
Fig. 4. NAHNP fails to inhibit TNF- production in TLR1/2, TLR3 or TLR5 activated 
macrophages. Quantification of TNF- from peritoneal macrophages isolated from wild-type 
mice (A) and mutant TLR4
Lps-d 
mice (B). Cells (1.5×10
5
 cells per well) were seeded to 24-
well-plates and were not treated (NT) or stimulated with LPS (20 ng/mL), poly (I:C) 
(10g/mL), flagellin (20 ng/mL) or PAM3CSK4 (20 ng/mL) for 24 hours in the presence or 
absence of 0.5 mg/mL NAHNP. Data are shown as mean SEM (n=3). 
Fig. 5. Effect of NAHNP on activation of downstream proteins of TLR4–NF-B signaling 
pathway. Primary macrophages were stimulated with LPS (20 ng/mL) in the presence (+) or 
absence (–) of NAHNP (0.5 mg/mL) for the indicated times. Cytosolic and nuclear extracts 
analyzed by western blot using antibodies directed against p-IRAK1, IB, RelA and p50. β-
actin served as loading control.  
Fig. 6. Concentration-dependent cytotoxicity of NAHNP in thioglycollate-elicited peritoneal 
macrophages. Cells (1.0×10
5
 cells per well) were seeded to 96-well-plates and were 
continuously exposed to nanoparticles at indicated concentrations for 24h in Opti-MEM

 I. 
Cell viability was measured by the WST-1 assay. The data are plotted as the percentage of 
absorbance in comparison with untreated controls and shown as mean SEM (n=4). 
Fig. 7. Evaluation of binding of nanoparticles to TLR4/MD2 receptor complex. (A) 
Representative overlay histogram of a FACS experiment: no fill, unlabeled macrophages; red 
fill, macrophages were stained with NAHNP-FITC for 30 min at 37°C; gray fill, macrophages 
were preincubated with anti-TLR4/MD2 antibody for 1 h at 37°C and stained with NAHNP-
FITC for 30 min. Shown are results from 1 of 3 representative experiments. (B) Fluorescence 
microscope images of living macrophages. (a-c) Cells were incubated with NAHNP-FITC 
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(green in b, c) for 30 min at 37°C. (d-f) Cells were pretreated with APC conjugated anti-
TLR4/MD2 antibody (red in e, f) for 1 h at 37°C before washing and incubating with 
NAHNP-FITC for 30 min. Hoechst 33342 staining (blue) was used to detect cell nuclei. 
Scale: 50m. (C) Quantification of TNF- from peritoneal macrophages. Cells (1.0×106 cells 
per well) were seeded to 24-well-plates and were not treated (NT) or stimulated with LPS (20 
ng/mL) for 30 min in the presence or absence of 0.1 mg/mL NAHNP-FITC. Data are shown 
as mean SEM (n=3). ** P  0.01.  
Fig. 8. Structure activity relationship data. Effect of glycol-splitting (A), 2-ODSNP, NDSNP, 
6-ODSNP, TDSNP (B), NAHDEC, NAHPEN and NAHOCT (C) on TNF- production from 
LPS stimulated mouse peritoneal macrophages. Cells (1.5×10
5 
cells/well) were seeded to 24-
well plate and were not treated (NT) or stimulated with LPS (20 ng/mL) with or without 
chemically-modified heparin derivatives (0.5 mg/mL) for 24 hours. Data are shown as mean 










































Fig. 3. Dose-dependent effect of NAHNP on TNF- production from LPS-stimulated 
























Fig. 7. Evaluation of binding of nanoparticles to TLR4/MD2 receptor complex. 
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Determination of critical micelle concentration (CMC) of NAHNP 
 
 






























































Supplementary Fig. S1. Plot of pyrene fluorescence intensity versus log concentrations 









Determination of partitioning coefficient of pyrene in NAHNP solutions 






where [Py]m and [Py]w are pyrene concentrations in the micellar and aqueous phases, 
respectively. The emission in NAHNP solutions is the sum of the emissions of probe in 
aqueous and micellar phases and can be expressed as follows: 
(𝐼𝑚𝑎𝑥 − 𝐼)/(𝐼 − 𝐼0) =
1 + (𝑃 − 1)
𝑃
 
where  is the volume portion of the micellar phase (=0.001 ([NAHNP]-CMC)); and I0 
and Imax are the intensities of pyrene at lower and higher concentrations of NAHNP. The 
experimental plots corresponding to this relationship are presented in Supplementary 
Fig. S2 and Kp values are determined from the slope of the experimental curves. 



































Supplementary Fig. S2. Plot of (Imax-I)/(I-I0) versus 
-1 obtained for pyrene (ex=339 nm, 




Determination of aggregation number of NAHNP 
The steady-state quenching data in microheterogeneous systems such as aqueous-
micellar solution do not fit simple Stern-Volmer kinetics, but have the following 
quenching kinetics:  
ln(I0/I)=[Q]/[M] 
where I and I0 are fluorescence intensities in the presence and absence of the quencher, 
[Q] is the bulk concentration of the quencher and [M] is the concentration of self-
assemblies. 
Plot of ln(I0/I) versus the concentration of CPC gives a straight line (Supplementary Fig. 







Supplementary Fig. S3. ln(I0/I) of pyrene fluorescence as a function of CPC 
concentration in the presence of NAHNP1 with DS 3.57% (left) and NAHNP10 with DS 
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Supplementary Fig. S4. Chemical structures of compounds.  D-erythro-sphingosine 
was attached to carboxylic groups of selectively 2-O-desulfated (2-ODSNP), 6-O-
desulfated (6-ODSNP), N-desulfated re-N-acetylated (NDSNP) and totally 
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Supplementary Fig. S5. Structures of lipid modified NAH derivatives.  D-erythro-
sphingosine of NAHNP was replaced with 1-octadecanamine (NAHOCT), 1-
decanamine (NAHDEC) or 1-pentanamine (NAHPEN) . 
